VIENNA, Va., Aug. 7 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION will conduct two interviews on Tuesday, August 8, 2006. In the interviews the CEO of CEL-SCI, Geert Kersten, will review current operations and discuss the future prospects. The first interview will be live on http://www.MN1.com at 11:30 a.m. eastern time. The second is a phone interview with Wallst.net that can be accessed through their website later that evening.
Interested parties may go to http://www.MN1.com to listen to management’s review of operations and discussion of future prospects. This live broadcast is available to anyone at any computer connected to the Internet. MN1.com is the only online destination that brings real microcap news to investors and features live interaction with companies from the AMEX, Bulletin Board, and Pink Sheets. Featuring Live Press Conferences, All-Day Live Trading Commentary, Analyst Profiles, Interactive Forums, News Items, and “The MicroBlog,” MN1.com gives microcap investors the information source necessary to trade in the markets. MN1.com boasts being the largest true news company reporting on microcap traded stocks.
The CEL-SCI Corporation interview with Wallst.net is available at http://www.wallst.net/. Wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. The website is a leading provider of financial news, media, tools and community- driven applications for investors. Wallst.net offers visitors free membership to its in-depth executive interviews, exclusive editorial content, breaking news, and several proprietary applications.
CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland. The Company’s lead product Multikine is cleared to enter global Phase III clinical trials in advanced primary head and neck cancer patients. CEL-SCI’s other products, which are currently in pre- clinical stage and are funded with U.S. government support, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense and avian flu.
CEL-SCI Corporation
CONTACT: COMPANY: Gavin de Windt of CEL-SCI Corporation, +1-703-506-9460;INVESTOR RELATIONS: Mike Lucci of Lucci Financial Group, LLC,+1-248-723-3330, for CEL-SCI Corporation
